Skip to main content
OTCMKTS:AHROQ

AtheroNova Competitors

$0.0060
-0.01 (-60.00 %)
(As of 05/13/2021 10:10 PM ET)
Add
Compare
Today's Range
$0.01
$0.01
50-Day Range
$0.01
$0.02
52-Week Range
$0.00
$0.06
Volume210,000 shs
Average Volume46,155 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta-8.71

Competitors

AtheroNova (OTCMKTS:AHROQ) Vs. ACUS, AFFY, ARYX, CBPI, CDSG, and CHHE

Should you be buying AHROQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to AtheroNova, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), China Botanic Pharmaceutical (CBPI), China Dongsheng International (CDSG), and China Health Industries (CHHE).

Acusphere (OTCMKTS:ACUS) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Volatility & Risk

Acusphere has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, indicating that its share price is 971% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Acusphere and AtheroNova, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
AtheroNova0000N/A

Earnings and Valuation

This table compares Acusphere and AtheroNova's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
AtheroNovaN/AN/AN/AN/AN/A

Profitability

This table compares Acusphere and AtheroNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
AtheroNovaN/AN/AN/A

Summary

Acusphere beats AtheroNova on 1 of the 1 factors compared between the two stocks.

Affymax (OTCMKTS:AFFY) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Volatility and Risk

Affymax has a beta of 2.77, indicating that its stock price is 177% more volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, indicating that its stock price is 971% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Affymax and AtheroNova, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affymax0000N/A
AtheroNova0000N/A

Earnings & Valuation

This table compares Affymax and AtheroNova's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AffymaxN/AN/AN/AN/AN/A
AtheroNovaN/AN/AN/AN/AN/A

Profitability

This table compares Affymax and AtheroNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AffymaxN/AN/AN/A
AtheroNovaN/AN/AN/A

Summary

Affymax beats AtheroNova on 1 of the 1 factors compared between the two stocks.

ARYx Therapeutics (OTCMKTS:ARYX) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Volatility and Risk

ARYx Therapeutics has a beta of -0.53, indicating that its stock price is 153% less volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, indicating that its stock price is 971% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for ARYx Therapeutics and AtheroNova, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ARYx Therapeutics0000N/A
AtheroNova0000N/A

Earnings & Valuation

This table compares ARYx Therapeutics and AtheroNova's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARYx TherapeuticsN/AN/AN/AN/AN/A
AtheroNovaN/AN/AN/AN/AN/A

Profitability

This table compares ARYx Therapeutics and AtheroNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ARYx TherapeuticsN/AN/AN/A
AtheroNovaN/AN/AN/A

Summary

ARYx Therapeutics beats AtheroNova on 1 of the 1 factors compared between the two stocks.

China Botanic Pharmaceutical (OTCMKTS:CBPI) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Earnings & Valuation

This table compares China Botanic Pharmaceutical and AtheroNova's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Botanic PharmaceuticalN/AN/AN/AN/AN/A
AtheroNovaN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for China Botanic Pharmaceutical and AtheroNova, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Botanic Pharmaceutical0000N/A
AtheroNova0000N/A

Profitability

This table compares China Botanic Pharmaceutical and AtheroNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Botanic PharmaceuticalN/AN/AN/A
AtheroNovaN/AN/AN/A

Volatility and Risk

China Botanic Pharmaceutical has a beta of 17.09, indicating that its stock price is 1,609% more volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, indicating that its stock price is 971% less volatile than the S&P 500.

Summary

China Botanic Pharmaceutical beats AtheroNova on 1 of the 1 factors compared between the two stocks.

AtheroNova (OTCMKTS:AHROQ) and China Dongsheng International (OTCMKTS:CDSG) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Volatility & Risk

AtheroNova has a beta of -8.71, indicating that its stock price is 971% less volatile than the S&P 500. Comparatively, China Dongsheng International has a beta of 13.38, indicating that its stock price is 1,238% more volatile than the S&P 500.

Valuation & Earnings

This table compares AtheroNova and China Dongsheng International's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtheroNovaN/AN/AN/AN/AN/A
China Dongsheng InternationalN/AN/AN/AN/AN/A

Profitability

This table compares AtheroNova and China Dongsheng International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtheroNovaN/AN/AN/A
China Dongsheng InternationalN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings for AtheroNova and China Dongsheng International, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AtheroNova0000N/A
China Dongsheng International0000N/A

Summary

China Dongsheng International beats AtheroNova on 1 of the 1 factors compared between the two stocks.

AtheroNova (OTCMKTS:AHROQ) and China Health Industries (OTCMKTS:CHHE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.

Volatility & Risk

AtheroNova has a beta of -8.71, indicating that its stock price is 971% less volatile than the S&P 500. Comparatively, China Health Industries has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.

Earnings & Valuation

This table compares AtheroNova and China Health Industries' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtheroNovaN/AN/AN/AN/AN/A
China Health Industries$9.93 millionN/A$3.55 millionN/AN/A

China Health Industries has higher revenue and earnings than AtheroNova.

Profitability

This table compares AtheroNova and China Health Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtheroNovaN/AN/AN/A
China Health Industries34.11%8.60%7.05%

Analyst Ratings

This is a breakdown of current recommendations and price targets for AtheroNova and China Health Industries, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AtheroNova0000N/A
China Health Industries0000N/A

Summary

China Health Industries beats AtheroNova on 5 of the 5 factors compared between the two stocks.


AtheroNova Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acusphere logo
ACUS
Acusphere
0.0$0.05-24.4%$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.09-28.1%$0.00N/A0.00High Trading Volume
ARYX
ARYx Therapeutics
0.0$0.02-46.7%$0.00N/A0.00High Trading Volume
Gap Up
CBPI
China Botanic Pharmaceutical
0.0$0.08-6.0%$0.00N/A0.00Gap Up
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.06-127.9%$0.00N/A0.00Gap Up
China Health Industries logo
CHHE
China Health Industries
0.4$0.25-19.8%$0.00$9.93 million4.20Upcoming Earnings
Gap Up
DDXSQ
Diadexus
0.0$0.00-0.0%$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04-14.3%$0.00N/A0.00Gap Up
FTCY
Global Future City
0.5$0.05-1.8%$0.00N/A0.00High Trading Volume
GLSI
Greenwich LifeSciences
2.0$32.95-3.6%$0.00N/A0.00
HRBR
Harbor Diversified
0.0$1.70-5.9%$0.00$263.61 million0.00Gap Down
IPAH
Interpharm
0.2$0.00-0.0%$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00-50.0%$0.00N/A0.00High Trading Volume
Gap Down
MBVXQ
MabVax Therapeutics
0.0$0.02-8.7%$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05-4.8%$0.00N/A0.00
NNBP
Nanobac Pharmaceuticals
0.0$0.00-0.0%$0.00N/A0.00
PARD
Poniard Pharmaceuticals
0.5$0.09-41.4%$0.00N/A0.00Gap Up
SGTI
Shengtai Pharmaceutical
0.2$0.02-0.0%$0.00N/A0.00Gap Down
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00-100.0%$0.00N/A0.00Gap Up
SUWN
Sunwin Stevia International
0.5$0.05-2.2%$0.00$26.09 million0.00Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03-12.1%$0.00N/A0.00Gap Up
SYNI
Synvista Therapeutics
0.0$0.00-0.0%$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00-0.0%$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01-3.0%$0.00N/A0.00High Trading Volume
Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.01-0.0%$0.00N/A0.00Gap Up
This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.